Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | MGLL | Q99685 | 5/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995976 | 0.86 | NR1H2 (0.53) | NR1H2MGLLPTGDR2MEN1KMT2A | |
| SCHEMBL2767134 | 0.85 | PTGDR2 (0.45) | MGLLPTGDR2ALDH1A1FAAH | |
| SCHEMBL2766969 | 0.84 | MGLL (0.51) | MGLLPTGDR2FAAH | |
| SCHEMBL2849484 | 0.83 | MGLL (0.49) | NR1H2MGLLPTGDR2KDM4EALDH1A1 | |
| SCHEMBL2849487 | 0.83 | MGLL (0.49) | NR1H2MGLLPTGDR2KDM4EALDH1A1 | |
| SCHEMBL2767197 | 0.83 | PTGDR2 (0.50) | MGLLPTGDR2KDM4EALDH1A1TDP1 | |
| SCHEMBL20912666 | 0.82 | NR1H2 (0.68) | NR1H2MGLLKDM4EALDH1A1ATM | |
| SCHEMBL20912771 | 0.82 | NR1H2 (0.68) | NR1H2MGLLKDM4EALDH1A1ATM | |
| SCHEMBL20912669 | 0.82 | NR1H2 (0.68) | NR1H2MGLLKDM4EALDH1A1ATM | |
| SCHEMBL15093715 | 0.81 | MGLL (0.61) | MGLLPTGDR2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GPR68, GPR88, GIPR | NR1H2 54/4885MGLL 1048/4885PTGDR2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.